

**Appendix 5 (as supplied by the authors): Cost of drugs for each Canadian province and territory**

Drug costs researched and compiled by Tiffany Czilli, B.Sc. Hon., Pharm.D., R.Ph., MD, CCFP

Therapy	ODB	NB	PEI	NS	NL	QC	MB	SK	AB	BC	YT	NWT	NUN	K&F	McK
Topical retinoids															
Retin A Cream 0.01% (g)	nb	nb	nb	nb	nb	0.36	nb	nb	nb	0.38	0.36	n/a	n/a	n/a	n/a
Retin A Cream 0.025% (g)	nb	nb	nb	nb	nb	0.36	nb	0.38	nb	0.38	0.36	n/a	n/a	n/a	n/a
Retin A Cream 0.05% (g)	nb	nb	nb	0.38	nb	0.35	nb	0.38	nb	0.42	0.37	0.41	0.41	0.41	0.41
Retin A Cream 0.1% (g)	nb	nb	nb	nb	nb	nb	nb	nb	nb	0.38	0.37	n/a	n/a	n/a	n/a
Retin A Gel 0.01% (g)	nb	nb	nb	nb	nb	nb	nb	0.75	nb	nb	0.37	nb	nb	n/a	n/a
Retin A Gel 0.025% (g)	nb	nb	nb	0.38	nb	0.35	nb	0.38	nb	0.42	0.37	nb	nb	0.41	0.41
Retin A Micro Gel 0.04% (g)	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	0.79	0.79
Retin A Micro Gel 0.1% (g)	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	0.79	0.79
Differin Cream (g)	nb	nb	nb	nb	nb	nb	nb	1.49	nb	nb	nb	1.57	1.57	1.57	1.57
Differin Gel (g)	nb	nb	nb	nb	nb	nb	nb	1.49	nb	nb	1	1.57	1.57	1.57	1.57
Differin Pledget 0.1% (g)	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	n/a	n/a
Differin XP (g)	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	1.05	1.05
Stieva A Cream 0.01% (g)	0.3	nb	nb	0.3	nb	0.29	nb	0.3	0.3	0.32	0.29	0.3	0.32	0.32	0.32
Stieva A Cream 0.025% (g)	0.3	nb	nb	0.3	nb	0.29	nb	0.3	0.3	0.32	0.29	0.3	0.32	0.32	0.32
Stieva A Cream 0.05% (g)	0.3	nb	nb	0.3	nb	0.29	nb	0.3	0.3	0.32	0.29	0.3	0.32	0.32	0.32
Stieva A Gel 0.01% (g)	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	0.29	nb	nb	n/a	n/a
Stieva A Gel 0.025% (g)	0.3	nb	nb	nb	nb	0.29	nb	0.3	nb	nb	0.29	0.32	0.32	0.32	0.32
Stieva A Gel 0.05% (g)	nb	nb	nb	nb	nb	nb	nb	0.3	nb	nb	0.29	0.32	0.32	0.32	0.32
Stieva A Forte 0.1% (g)	nb	nb	nb	0.30g	nb	0.29	nb	0.3	0.3	nb	0.29	0.3	0.32	0.32	0.32
Stieva A Solution 0.025% (mL)	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	0.19	0.19	0.19	0.19
Stieva A Solution 0.05% (mL)	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	nb	n/a	n/a	n/a
Stievamycin Mild (g)	nb	nb	nb	0.84	nb	nb	nb	0.84	0.9	0.54	0.84	0.91	0.91	0.91	0.91
Stievamycin Gel 0.025/4 (g)	0.84	nb	nb	0.84	nb	nb	nb	0.84	0.9	0.54	0.84	0.91	0.91	0.91	0.91
Stievamycin Forte Gel (g)	nb	nb	nb	0.84	nb	nb	nb	0.84	0.9	nb	0.84	0.91	0.91	0.91	0.91
Tazorac 0.05% Crmel (g)	nb	nb	nb	1.36	nb	nb	nb	1.36	1.36	1.47	1.32	1.36	1.44	1.44	1.44
Tazorac 0.1% Crmel (g)	nb	nb	nb	1.36	nb	nb	nb	1.36	1.36	1.47	1.32	1.36	1.44	1.44	1.44
Therapy	ODB	NB	PEI	NS	NL	QC	MB	SK	AB	BC	YT	NWT	NUN	K&F	McK
Antibiotics															
Minocycline 50 (t)	nb	0.31	0.31	0.31	0.35	0.31	0.54	0.31	0.31	0.33	0.54	0.31	0.54	0.54	0.54
Minocycline 100 (t)	nb	0.59	0.59	0.59	0.68	0.59	1.03	0.59	0.59	0.64	1.03	0.59	1.03	1.03	1.03
Minocin 50 (t)	nb	0.31	0.31	nb	0.7	0.61	nb	nb	nb	nb	0.61	c	0.65	0.65	0.65

Appendix to: Asai Y, Baibergenova A, Dutil M, et al. Management of acne: Canadian clinical practice guideline.  
CMAJ 2015. DOI:10.1503/cmaj.140665. Copyright © 2015 8872147 Canada Inc. or its licensors

Minocin 100 (t)	nb	0.59	0.59	nb	1.36	nb	nb	nb	nb	nb	c	1.25	1.25	1.25
Doxycycline 100 (t)	nb	0.59	0.59	0.59	0.67	0.59	0.64	0.59	0.59	0.63	0.59	0.59	0.59	0.59
Tetra 250 (t)	0.07	0.06	nb	0.07	nb	0.07	nb	0.07	0.07	0.07	0.05	0.07	0.07	0.07
Erythromycin 250 (t)	0.23	0.56	0.42	0.42	0.55	nb	nb	0.49	0.42	0.43	0.48	0.42	0.2	0.2
Apprilon 40 (t)	nb	nb	2.69	2.69										
Clindamycin 1% (mL)	nb	0.24	0.23	0.23	nb	0.18	0.25	0.23	nb	0.24	0.23	0.23	0.23	0.23
Dalacin T (mL)	nb	0.24	0.23	0.23	nb	0.3	0.36	0.33	nb	0.33	0.35	0.35	0.35	0.35
Clindets (wipe)	nb	0.72	0.72	0.72										
Vibramycin 100 (t)	nb	0.59	0.59	0.59	1.99	1.65	nb	1.73	1.73	0.63	1.7	nb	1.85	1.85
Hormonal therapies														
Tri-cyclen 21 (t)	0.96	nb	nb	0.96	nb	0.6	nb	0.99	0.83	1.04	0.73	0.83	1.03	1.03
Alesse 21(t)	0.71	0.46	0.46	0.46	0.83	0.61	0.78	0.71	0.71	0.5	0.69	0.71	0.77	0.77
Alysexa/Aviane 21 (t)	0.46	0.46	0.46	0.46	0.53	0.46	0.46	0.46	0.46	0.5	0.46	0.46	0.46	0.46
Diane 35 (t)	nb	nb	1.11	nb	nb	nb	1.7	nb	nb	nb	1.39/tan	1.66	1.66	1.66
Cyestra (t)	nb	nb	1.11	nb	nb	nb	1.22	nb	nb	nb	nb	1.2	1.2	1.2
Yaz (t)	0.55	nb	nb	nb	nb	0.42	nb	0.55	nb	0.6	nb	0.58	0.58	0.58
Yasmin 21 (t)	0.57	nb	nb	0.57	nb	0.56	nb	0.57	0.57	0.62	0.69	0.57	0.6	0.6
Oral isotretinoin														
Accutane 10 (t)	0.93	0.93	0.93	0.93	nb	0.93	1.02	0.93	0.93	1	1.7	0.93	0.98	0.98
Clarus 10 (generic) (t)	0.93	0.93	0.93	0.93	nb	0.93	1.02	93	0.93	1	nb	0.93	0.93	0.93
Accutane 40 (t)	1.9	1.9	1.9	1.9	nb	1.9	2.09	1.9	1.9	2.05	3.49	1.9	2.01	2.01
Clarus 40 (t)	1.9	1.9	1.9	1.9	nb	1.9	2.09	1.9	1.9	2.05	nb	1.9	1.9	1.9
Epuris 10 (t)	nb	ur	nb	nb	nb	nb	1.13							
Epuris 20 (t)	nb	ur	nb	nb	nb	nb	1.52							
Epuris 30 (t)	nb	ur	nb	nb	nb	nb	1.91							
Epuris 40 (t)	nb	ur	nb	nb	nb	nb	2.31							
Therapy	ODB	NB	PEI	NS	NL	QC	MB	SK	AB	BC	YT	NWT	NUN	K&F
Topical combinations														
Benzacln (g)	0.92	nb	nb	nb	nb	nb	nb	0.92	0.91	nb	0.85	nb	0.98	0.98
Benzac 10 AC Gel (g)	nb	0.36	0.27	0.35	0.35	0.35	0.35							
Benzac W10 Wash (g)	nb	0.15	0.11	0.14	0.14	0.14	0.14							
Clindoxyl (g)	0.91	nb	nb	nb	nb	nb	nb	0.92	0.91	nb	0.89	nb	0.91	0.91
Tactuo (g)	nb	nb	1.57	1.57										
Biacna (g)	nb	nb	1.11	1.11										
Dapsone														
Aczone (g)	nb	nb	1.09	1.09										

Appendix to: Asai Y, Baibergenova A, Dutil M, et al. Management of acne: Canadian clinical practice guideline. CMAJ 2015. DOI:10.1503/cmaj.140665. Copyright © 2015 8872147 Canada Inc. or its licensors

Benzoyl Peroxide														
Panoxy 10 (g)	0.15	nb	nb	nb	nb	nb	nb	0.14	nb	0.16	0.15	c	0.15	0.15
Panoxy 20 (g)	0.19	nb	nb	nb	nb	nb	nb	0.19	nb	0.21	0.19	c	0.2	0.2
Sulfacet (g)	nb	nb	nb	0.99	nb	nb	nb	0.99	0.98	1.07	0.88	nb	1.05	1.05
Finacea (azelaic acid) (g)	nb	nb	nb	0.6	nb	0.6	nb	0.6	0.6	0.65	nb	0.6	0.63	0.63
ODB: Ontario Drug Benefit; NB: New Brunswick; PEI: Prince Edward Island; NS: Nova Scotia; NL: Newfoundland and Labrador; QC: Quebec; MB: Manitoba; SK: Saskatchewan; AB: Alberta; BC: British Columbia; YT: Yukon; NWT: Northwest Territories; NUN: Nunavut; K&F: Kohl and Frisch; McK: McKesson Ontario														
All figures given in Canadian dollars; nb: not a benefit for indicated formulary; n/a: not supplied by wholesaler g:gram; mL:millilitre; t: tablet														